Gstaad – September 16, 2026 -- Tomonari Abe, President of 295-year-old Abe Yoando Pharma Co., Ltd., has become the first Japanese speaker in the history of the Longevity Investors Conference, running September 14-17, 2026 in Gstaad, Switzerland.
Global longevity market poised to hit $8 trillion by 2030
The healthy longevity sector is projected to reach approximately $8 trillion by 2030, according to a UBS Chief Investment Office research report cited by the company. International investors are increasingly focused on Japan's aging population as a testing ground for longevity science and market validation ahead of other nations.
Tokyo pharma pioneer presents Asia growth strategy to global investors
Abe will deliver a session titled "The Longevity Opportunity in Asia: Building the Infrastructure for an Aging World," outlining scalable growth models originating from Japan's demographic and scientific landscape. "By combining nearly three centuries of traditional expertise with cutting-edge bioscience, we aim to demonstrate scalable, global growth strategies originating from Asia," Abe said.
Company advances NMN research after XPRIZE Healthspan finalist selection
Abe Yoando Pharma, founded in 1731 as official physicians to the shogun of the Matsudaira clan, was named one of 20 finalist teams out of 799 entries from 58 countries in the global XPRIZE Healthspan competition. The company's current research focuses on high-purity nicotinamide mononucleotide (NMN) and joint academic studies examining cellular mechanisms including sirtuin genes, part of broader international collaboration on healthy aging science.